On August 27, NVHPF hosted a Discussion of International Reference Pricing in New CMMI Drug Models
The U.S. Centers for Medicare & Medicaid Services (CMS) which oversees the Medicare and Medicaid programs that serve over 100 million Americans, is piloting limitations on payments for pharmaceuticals based on other countries’ public health care policies.
When the Center for Medicare and Medicaid Innovation (CMMI) linked domestic public reimbursement to an international price floor, it effectively converted a localized cost-containment experiment into a highly volatile cross-border game theory matrix. Many large pharmaceutical manufacturers are not U.S.-based companies, but U.S. sales often comprise the majority of their revenue when compared to their sales in the rest of the world. As the regulatory framework transitions toward mandatory nationwide tracking under the GENEROUS, GLOBE, and GUARD models, policymakers are rewriting the rules of transatlantic trade and clinical access.
On August 27, Dr. Stefan Walzer, CEO, President & Founder of MArS Market Access & Pricing Strategy GmbH, and Brittany La Couture, Vice President of Health Policy at Applied Policy joined Applied Policy President and CEO Jim Scott for a discussion of these pricing initiatives and how the practical effect on manufacturers, payers, and foreign governments cannot be considered in isolation.